“The [WHO’s] release this week of interim policy guidelines on the use of bedaquiline for treatment of multidrug-resistant tuberculosis [MDR-TB] offers hope to patients and their physicians running out of options to treat the disease, but the document also highlights the need for more research, selective use, and vigilant roll out of the first new approach to TB treatment in nearly half a century,” the Center for Global Health Policy’s “Science Speaks” blog reports. “WHO’s interim guidance is a necessary step but leaves much to be done, cautioned Erica Lessem of Treatment Action Group’s TB/HIV project,” the blog writes, adding, “The drug has only been approved for use in the United States, and the manufacturer has only filed applications for approval of its use in a handful of other countries, she noted” (Aziz, 6/14).